ArticleThe Journal of cell biology2019
The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of cell biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 48 citations in OpenAlex.
- LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation.British journal of cancer · 2026Article
- PHLPP is neither a Phosphatase nor a Tumor Suppressor.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026Review
- Escape from TGF-β-induced senescence promotes aggressive hallmarks in epithelial hepatocellular carcinoma cells.Molecular oncology · 2025Article
- PHLPP2 is a pseudophosphatase that lost activity in the metazoan ancestor.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Genome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesothelioma.Cell death & disease · 2025Article
- Neuronal alterations in AKT isotype expression in schizophrenia.Molecular psychiatry · 2025Article
- LncRNA CCAT1 knockdown suppresses tongue squamous cell carcinoma progression by inhibiting the ubiquitination of PHLPP2.Molecular and cellular biochemistry · 2025Article
- Phlpp1 alters the murine chondrocyte phospho-proteome during endochondral bone formation.Bone · 2024Article
- Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function.Science (New York, N.Y.) · 2024Article
- Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer.Cancer discovery · 2024Article
- Targeting the autophagy-miRNA axis in prostate cancer: toward novel diagnostic and therapeutic strategies.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- A germline point mutation in the MYC-FBW7 phosphodegron initiates hematopoietic malignancies.Genes & development · 2024Article
- Neuronal alterations in AKT isotype expression in schizophrenia.Research square · 2024Article
- PHLPP2: A Prognostic Biomarker in Adenocarcinoma of the Rectum.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- FKBP51 plays an essential role in Akt ubiquitination that requires Hsp90 and PHLPP.Cell death & disease · 2023Article
- Investigating the role of common and rare variants in multiplex multiple sclerosis families reveals an increased burden of common risk variation.Scientific reports · 2022Article
- PHLPP Signaling in Immune Cells.Current topics in microbiology and immunology · 2022Review
- On the PHLPPside: Emerging roles of PHLPP phosphatases in the heart.Cellular signalling · 2021Review
- Emerging roles of PHLPP phosphatases in metabolism.BMB reports · 2021Review
- Pleckstrin homology (PH) domain and Leucine Rich Repeat Phosphatase 1 (Phlpp1) Suppresses Parathyroid Hormone Receptor 1 (Pth1r) Expression and Signaling During Bone Growth.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 4 institutions in 1 country.
Dawid G NowakCold Spring Harbor Laboratory, Cold Spring Harbor, NY dgn2001@med.cornell.edu.
Ksenya Cohen KatsenelsonDepartment of Pharmacology, University of California San Diego, La Jolla, CA.
Kaitlin E WatrudCold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Muhan ChenCold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Grinu MathewCold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Vincent D D'AndreaCold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Matthew F LeeCold Spring Harbor Laboratory, Cold Spring Harbor, NY.ORCID 0000-0002-5110-6601
Manojit Mosur SwamynathanCold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Irene Casanova-SalasCold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Megan C JibilianDivision of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY.
Caroline L BuckholtzDivision of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY.
Alexandra J AmbricoCold Spring Harbor Laboratory, Cold Spring Harbor, NY.ORCID 0000-0001-6372-1057
Chun-Hao PanCold Spring Harbor Laboratory, Cold Spring Harbor, NY.ORCID 0000-0002-0776-9408
John E WilkinsonDepartment of Pathology, University of Michigan, Ann Arbor, MI.
Alexandra C NewtonDepartment of Pharmacology, University of California San Diego, La Jolla, CA.
Lloyd C TrotmanCold Spring Harbor Laboratory, Cold Spring Harbor, NY trotman@cshl.edu.ORCID 0000-0002-4794-1559
Cold Spring Harbor Laboratory · USCornell University · USUniversity of California San Diego · USUniversity of Michigan · US
Funding
Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI John Edward Moses · 1987 to 2026
$118.9MContemporary Approaches to Cancer Cell Signaling and CommunicationT32CA009523 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DONOGHUE, DANIEL J, YANG, JING · 1985 to 2025
$12.1MWeill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 2017 to 2021
$10.9MMolecular Mechanisms of Cell SignalingR35GM122523 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALEXANDRA C. NEWTON · 2017 to 2026
$6.7MMechanisms and Treatment of PTEN Mutant Prostate TumorigenesisR01CA137050 · NCI · COLD SPRING HARBOR LABORATORY · PI TROTMAN, LLOYD C · 2010 to 2018
$3.1MRegulation of Receptor Tyrosine KinasesR01GM065490 · NIGMS · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI DONOGHUE, DANIEL J · 2002 to 2005
$1.0MNCI NIH HHS P30 CA045508NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA137050NCI NIH HHS T32 CA009523NIGMS NIH HHS R01 GM065490NIGMS NIH HHS R35 GM122523
Abstract
Metastatic prostate cancer commonly presents with targeted, bi-allelic mutations of the
Indexed as
AnimalsCell ProliferationDisease ProgressionHumansMaleMiceMice, KnockoutNeoplasm MetastasisPhosphoprotein PhosphatasesPhosphorylationProstatic NeoplasmsProtein StabilityProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mycPTEN PhosphohydrolaseSignal TransductionMyc protein, mousePHLPP2 protein, mousePhosphoprotein PhosphatasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mycPTEN PhosphohydrolasePten protein, mouseSmall Molecule LibrariesTrp53 protein, mouseTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.